The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
  • Email Email
  • Comments Comments
  •  (1)
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Press Release

Newly-Unsealed Documents Shed Light on Abbott Labs' 400% Norvir Price Hike

Union, Consumer Groups Decry Abbott for Putting Profits Before HIV/AIDS Patients' Needs

May 12, 2008

Boston, MA -- In an ongoing nationwide class action lawsuit against Abbott Laboratories, Inc. (NYSE: ABT), the Court in the case recently ordered the unsealing of documents regarding Abbott's four-hundred percent price increase of the HIV/AIDS drug NorvirĀ®.

Abbott fought to keep these documents sealed, arguing that they contain 'business strategies' important to Abbott's competitive position in the HIV pharmaceutical market. But Judge Claudia Wilken ruled that because the price increase related to the "allegations that are central to Plaintiff's anti-trust claims" the documents should be unsealed. (Order, p. 3).

View Full Article

  • Email Email
  • Comments Comments
  •  (1)
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

See Also
More on HIV Medications
More News on Kaletra (Lopinavir/Ritonavir)

Reader Comments:

Comment by: DAVID MONDEJAR (KINGSTON,, NY 12401) Sat., Sep. 13, 2008 at 11:29 pm UTC
What everyone suspected has just proven to be true!
These big pharmaceutical companies could care less about researching a cure, they make millions of dollars keeping people on "Maintenance drugs".
Corporate "Greed" in this country has gone out of control and I will live to see the day when the big "backlash" comes!
Reply to this comment

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining: